CG
AZN icon

Caprock Group’s AstraZeneca AZN Stock Holding History

Caprock Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,970
Closed -$4.04M – 1128
2025
Q4 		$4.04M Buy
21,970
+2,672
+14% +$469K 0.09% 197
2025
Q3 		$3.1M Buy
+19,298
New +$2.92M 0.08% 228
2025
Q1 		$2.53M Buy
17,222
+3,357
+24% +$486K 0.08% 230
2024
Q4 		$1.82M Buy
13,865
+1,800
+15% +$252K 0.06% 287
2024
Q3 		$1.88M Buy
12,065
+44
+0.4% +$7.1K 0.07% 245
2024
Q2 		$1.88M Buy
12,021
+6,796
+130% +$1.02M 0.08% 222
2024
Q1 		$708K Buy
5,225
+619
+13% +$82K 0.04% 319
2023
Q4 		$620K Sell
4,606
-948
-17% -$123K 0.04% 340
2023
Q3 		$752K Buy
5,554
+131
+2% +$17.9K 0.06% 264
2023
Q2 		$776K Buy
5,423
+313
+6% +$46.1K 0.06% 265
2023
Q1 		$709K Buy
5,110
+855
+20% +$115K 0.06% 270
2022
Q4 		$577K Sell
4,255
-12
-0.3% -$1.5K 0.05% 255
2022
Q3 		$468K Sell
4,267
-464
-10% -$58.9K 0.05% 289
2022
Q2 		$625K Sell
4,731
-91
-2% -$11.9K 0.06% 228
2022
Q1 		$640K Buy
4,822
+1,508
+46% +$181K 0.06% 246
2021
Q4 		$386K Sell
3,314
-963
-23% -$113K 0.03% 350
2021
Q3 		$514K Buy
4,277
+1,219
+40% +$142K 0.05% 251
2021
Q2 		$366K Sell
3,058
-2,747
-47% -$301K 0.03% 309
2021
Q1 		$577K Sell
5,805
-336
-5% -$33.8K 0.06% 217
2020
Q4 		$614K Buy
6,141
+1,105
+22% +$117K 0.07% 205
2020
Q3 		$552K Buy
5,036
+564
+13% +$62.7K 0.08% 189
2020
Q2 		$473K Sell
4,472
-82
-2% -$8.47K 0.07% 203
2020
Q1 		$407K Buy
4,554
+1,348
+42% +$127K 0.08% 181
2019
Q4 		$320K Buy
3,206
+69
+2% +$6.5K 0.06% 237
2019
Q3 		$280K Buy
3,137
+284
+10% +$24.6K 0.05% 249
2019
Q2 		$236K Sell
2,853
-327
-10% -$25.6K 0.05% 272
2019
Q1 		$257K Buy
3,180
+322
+11% +$25.4K 0.05% 288
2018
Q4 		$217K Buy
+2,858
New +$223K 0.05% 297
2016
Q4 		– Sell
-5,400
Closed -$355K – 347
2016
Q3 		$355K Buy
5,400
+414
+8% +$27.1K 0.08% 227
2016
Q2 		$301K Sell
4,986
-735
-13% -$42.7K 0.07% 212
2016
Q1 		$322K Buy
+5,721
New +$344K 0.08% 217

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Caprock Group's AZN Position: Q1 2026 in Review

Caprock Group sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 21,970 shares — an estimated $4.04M sold.

Caprock Group first reported a position in AZN in Q1 2016 and held it in 31 quarters. The position peaked at $4.04M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Caprock Group reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Caprock Group sold 21,970 AstraZeneca shares in Q1 2026, an estimated $4.04M.
  • Caprock Group first reported a position in AstraZeneca in Q1 2016 and held it in 31 quarters.
  • Caprock Group's AstraZeneca position peaked at $4.04M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.